Amgen is trading at $407.27, down 6.17% after hours, with no reliable report confirming a new company announcement or late-breaking event behind the decline. - The move is versus the October 15 regular-session close of $434.03. - The positive Tezspire Phase 3 CROSSING results reported October 14 were earlier news; nearly 70% on the higher dose achieved remission at week 24. - Broader market signals were mixed, and available evidence does not establish a market-wide cause.